Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06218914 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Endometrial Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
- 18
- Study locations
NCT06218914 is a Phase 1 study of Non-Small Cell Lung Cancer and Endometrial Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 108 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (84% lower). The trial reports 18 study locations across 12 states.
The verdict
NCT06218914, a Phase 1 study of Non-Small Cell Lung Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
- 18
- Study locations
Study Summary
Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
Conditions Studied
Interventions
- BIOLOGICAL NT-112: Autologous, engineered T Cells targeting KRAS G12D
- BIOLOGICAL AZD0240: Autologous, engineered T Cells targeting KRAS G12D
Study Locations (18)
California
- Research Site - Duarte
- Research Site - Los Angeles
- Research Site - Newport Beach
Texas
- Research Site - Dallas
- Research Site - Galveston
- Research Site - Houston
New York
- Research Site - New York
- Research Site - New York
Pennsylvania
- Research Site - Philadelphia
- Research Site - Pittsburgh
Florida
- Research Site - Jacksonville
Illinois
- Research Site - Chicago
Kansas
- Research Site - Westwood
Massachusetts
- Research Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2024-03-22 |
| Est. Completion | 2043-11-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06218914
The ClinicalTrials.gov registry entry for NCT06218914 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (84% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which NT-112: Autologous, engineered T Cells targeting KRAS G12D is the first listed.
NCT06218914 reports 18 study locations spanning 12 distinct geographic areas - top geographies include California, Texas, New York.
Frequently Asked Questions
What is clinical trial NCT06218914 about?
NCT06218914 is a clinical study titled "Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors". Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
What is the current status of trial NCT06218914?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2024-03-22. Estimated completion is 2043-11-18.
What conditions does trial NCT06218914 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Endometrial Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor, Adult, Colorectal Carcinoma.
What interventions are being tested in trial NCT06218914?
The interventions under investigation include: NT-112: Autologous, engineered T Cells targeting KRAS G12D (BIOLOGICAL), AZD0240: Autologous, engineered T Cells targeting KRAS G12D (BIOLOGICAL).
Who is sponsoring clinical trial NCT06218914?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06218914 being conducted?
This trial has 18 study locations across California, Florida, Illinois, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.